UNSPSC 51432508: Methoserpidine

This classification denotes an antiadrenergic agent with the molecular formula C33H40N2O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8F8C1JQH53, chemically known as (-)-10-METHOXYDESERPIDINE but generally known as methoserpidine, which bears US NIH Compound Identifier 297930. The term methoserpidine is an International Non-Proprietary Name or INN. European Medicines Agency schedules methoserpidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08855MIG.

Most nations schedule methoserpidine under HS 29399900 and SITC 54149. As of Q4 2014, METHOSERPIDINE remains the US FDA Preferred Term for this commodity. SMILES: COC1C(CC2CN3CCC4=C(C3CC2C1C(=O)OC)NC5=C4C=C(C=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC.

UNSPSC 51432508 Methoserpidine is a Commodity code that captures pharmaceutical products supplied to state and local health agencies, emergency services, and multistate purchasing cooperatives. State and local governments procure under this code to stock emergency medications, maintain pharmacy benefit programs, and support direct-to-manufacturer supply chains for public employee health plans and agency operations. Issuing bodies include municipal fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances. The City of Tampa's Fire Rescue department, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the range of buyers currently active under the code—from local emergency services with immediate medication needs to state-level pharmacy benefit managers and cooperative purchasing vehicles serving multiple jurisdictions.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa issued IFB 26P00188 in April 2026 for advanced life support medications including Labetalol, Epinephrine, Adenosine, and Diltiazem—four specific medication line items totaling an estimated contract value of $40,000.00, with delivery required within ten calendar days and a response deadline of April 8, 2026. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels, signaling a shift toward negotiated net pricing models. The Minnesota Department of Administration, administering MMCAP, issued RFP S1070000015802 due March 26, 2026 to establish multistate contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers to state and local government facilities in Minnesota and Oregon, with contract terms effective July 1, 2026. The Tampa bid included a 5 percent SLBE discount not to exceed $10,000 and required Safety Data Sheets compliant with OSHA standards; the MMCAP RFP weighted price competitiveness at 75 percent and required cGMP and Drug Supply Chain Security Act compliance.